Merck's Anfulchang® (Clerovimab) commercially launched in China

Glonghui September 9th｜According to Merck China, Merck (MRK.N) recently announced that the world’s first single fixed-dose long-acting RSV monoclonal antibody, Clarieva monoclonal antibody injection, has officially been commercially launched in China. It is intended for the prevention of lower respiratory tract infections caused by respiratory syncytial virus (RSV) in newborns and infants who are about to enter or be born during their first RSV season. There is no need to measure body weight, as the same dose is administered to all, providing a new option to help safeguard the respiratory health of babies in China.